切除的黑色素瘤中辅助性程序性死亡受体1（PD-1）阻断：预防复发就足够了吗？
Adjuvant PD-1 Blockade in Resected Melanoma: Is Preventing Recurrence Enough?
作者信息
Smithy James W, Shoushtari Alexander N
机构信息
Memorial Sloan Kettering Cancer Center, New York, New York.
Weill Cornell Medical College, New York, New York.
出版信息
Cancer Discov. 2022 Mar 1;12(3):599-601. doi: 10.1158/2159-8290.CD-21-1593.
Grossmann and colleagues report the results of a large randomized trial demonstrating improved recurrence-free survival with adjuvant pembrolizumab in resected melanoma compared with adjuvant ipilimumab or IFNα2b. However, it remains unclear whether adjuvant immunotherapies extend overall survival as outcomes for patients with advanced melanoma continue to improve. See related article by Grossmann et al., p. 644 (1).
格罗斯曼及其同事报告了一项大型随机试验的结果，该试验表明，与辅助性伊匹木单抗或干扰素α2b相比，辅助性帕博利珠单抗用于切除后的黑色素瘤可改善无复发生存率。然而，随着晚期黑色素瘤患者的预后持续改善，辅助性免疫疗法是否能延长总生存期仍不清楚。见格罗斯曼等人的相关文章，第644页(1)。
Zotero 插件